CTRI/2021/06/034341
Completed
未知
Efficacy, Safety and Quality of Life with different Itraconazole regimens in Recurrent Tinea Corporis and Tinea Cruris: An Interventional Study
Pt BD Sharma PGIMS Rohtak0 sites72 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Sponsor
- Pt BD Sharma PGIMS Rohtak
- Enrollment
- 72
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patient 18\-65 years of age of either gender
- •2\. Patient who has recurrence of lesions of tinea corporis and tinea cruris in less than 6 weeks after clinical cure
- •3\. Patient willing to provide written informed consent.
- •4\. Patients willing to come for regular follow up.
Exclusion Criteria
- •1\. Patient who has recurrence of lesions of tinea corporis and tinea cruris in less than 6 weeks after completion of treatment with Itraconazole and having been cured clinically.
- •2\. Patient suffering from tinea infections other than tinea corporis and tinea cruris.
- •3\. Patients with a history of intolerance or hypersensitivity to the study drugs.
- •4\. Patients who have serious concomitant illness which can prevent the completion of study.
- •5\. Patients with contact dermatitis, atopic dermatitis, psoriasis or any other skin disease.
- •6\. All pregnant and breastfeeding females.
- •7\. Patients with hepatic, renal or cardiac disease.
- •8\. Patients on drugs that are contraindicated for use with itraconazole, which include pimozide, dofetilide, quinidine, oral midazolam, triazolam, nisoldipine, felodipine, dihydroergotamine, ergotamine, ergometrine, methylergometrine, cisapride, lovastatin, simvastatin, levacetylmethadol, and methadone.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003759-40-ESovartis Pharma AG1,760
Active, not recruiting
Phase 1
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003759-40-DEovartis Pharma AG1,760
Active, not recruiting
Phase 1
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003759-40-LVovartis Pharma AG1,760
Active, not recruiting
Phase 1
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003759-40-EEovartis Pharma AG1,760
Active, not recruiting
Phase 1
Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol, is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.HypercholesterolemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-003759-40-BGovartis Pharma AG1,760